NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
Clinical Trials
9 trialsNCT01502085 2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2 Completed
NCT01297764 2026-03-23
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT00616967 2026-03-05
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT06693284 2026-02-03
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
University of Minnesota
Phase EARLY_PHASE1 Recruiting
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT03842696 2026-01-27
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting